Kodiak Sciences (KOD) Stock Price
Kodiak Sciences Price
The consensus 12-month price target for Kodiak Sciences is 59.50 USD, about 34.1% below where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Kodiak Sciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Kodiak Sciences business model & stock analysis
Frequently asked questions about Kodiak Sciences
The business model of Kodiak Sciences Inc. focuses on discovering, developing, and commercializing novel therapies for retinal diseases. With a particular emphasis on diseases like age-related macular degeneration (AMD) and diabetic retinopathy, the company is dedicated to improving the lives of patients with vision-threatening conditions. Kodiak Sciences Inc. utilizes its proprietary technology platform, known as the Antibody Biopolymer Conjugate (ABC) platform, to create innovative biologics that provide extended duration treatment options. By combining cutting-edge science and a patient-centric approach, Kodiak Sciences Inc. aims to revolutionize the treatment landscape for retinal diseases.
Kodiak Sciences Inc is primarily active in the biotechnology industry.
The main competitors of Kodiak Sciences Inc in the market include companies such as Regeneron Pharmaceuticals Inc, Novartis AG, and Roche Holding AG.
Kodiak Sciences Inc, founded in 2009, is a clinical-stage biopharmaceutical company focused on developing novel therapies for treating retinal diseases. The company is headquartered in Palo Alto, California. Kodiak Sciences Inc specializes in discovering and developing innovative medicines using its proprietary antibody biopolymer conjugate (ABC) platform. The platform enables the creation of optimized, potent, and durable therapies for various ocular diseases. Kodiak Sciences Inc has made significant progress in developing therapies for retinal diseases, including age-related macular degeneration and diabetic eye disease. With a strong commitment to research and development, Kodiak Sciences Inc aims to improve the lives of patients suffering from vision-threatening diseases.
Kodiak Sciences Inc has achieved several significant milestones. The company successfully completed a Phase 1b clinical trial for its lead product candidate, KSI-301, demonstrating its potential as a highly effective therapy for retinal diseases. Kodiak Sciences also received Fast Track designation from the U.S. FDA for KSI-301, highlighting the potential for expedited development and review. Additionally, the company entered into a strategic collaboration with Biogen, a global biotechnology leader, to develop and commercialize potential future products based on Kodiak's novel antibody biopolymer conjugate platform. These milestones illustrate the company's progress in advancing innovative therapies and forging key partnerships in the biopharmaceutical industry.
Kodiak Sciences Inc is primarily present in the United States.
Kodiak Sciences Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. With a vision to revolutionize the treatment of retinal diseases, Kodiak Sciences Inc fosters a corporate philosophy rooted in scientific rigor and patient-centricity. The company strives to develop transformative therapies addressing unmet medical needs, placing a strong emphasis on advanced research and development. By leveraging its proprietary technology platforms, Kodiak Sciences Inc aims to provide patients with effective and safe treatment options. With a focus on improving the quality of life for individuals affected by retinal diseases, Kodiak Sciences Inc remains dedicated to advancing ophthalmic healthcare.
Analysts currently set an average price target of 63.75 USD for the Kodiak Sciences stock (median: 59.50 USD), implying -29.4 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Kodiak Sciences stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Kodiak Sciences to generate revenue of 11.32 M USD and earnings per share of -4.68 USD.
Converted at the current exchange rate, the Kodiak Sciences share trades at 80.42 EUR (90.27 USD).
The Kodiak Sciences share (KOD) is listed on 4 stock exchanges, including: NASDAQ (KOD), Frankfurt (K27.F), München (K27.MU), Düsseldorf (K27.DU).
Kodiak Sciences Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of various eye diseases. The company was founded in 2009 and is headquartered in Palo Alto, California.
The expected revenue of Kodiak Sciences is 11.32 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Kodiak Sciences is -248.82 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Kodiak Sciences is currently -19.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kodiak Sciences stock.
The price-to-sales ratio (P/S) of Kodiak Sciences is currently 424.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kodiak Sciences stock.
The Eulerpool Quality Score for Kodiak Sciences is 2/10.
The ISIN of Kodiak Sciences is US50015M1099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Kodiak Sciences is A2N6P0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Kodiak Sciences is KOD. The ticker symbol is used to trade Kodiak Sciences shares on the stock exchange.
Kodiak Sciences stock
Kodiak Sciences Peer Group
Kodiak Sciences Ticker
Kodiak Sciences FIGI
All fundamentals and in-depth analysis of Kodiak Sciences
Our stock analysis for Kodiak Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kodiak Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.